Forte Biosciences Inc. Experiences Surge in Stock Following Positive Celiac Disease Trial Results

In a significant development for Forte Biosciences Inc., the biotech company’s stock experienced a remarkable surge of 25% on Monday, following the announcement of positive results from a Phase 1b trial of its lead program, FB102, aimed at treating celiac disease. This promising data has set the stage for the initiation of the Phase 2 trial, with top-line results anticipated in the first half of 2026.

The Phase 1b study demonstrated statistical significance in several key areas, including a notable change in the density of CD3-positive T cells and a 42% benefit for patients during the gluten challenge. These results have not only bolstered investor confidence but have also positioned Forte Biosciences as a strong contender in the biopharmaceutical landscape, particularly in the realm of autoimmune and autoimmune-related diseases.

Despite a challenging year-to-date performance, with shares down by 35.45%, the company has seen a 19.67% rally over the past 12 months. This recent surge reflects a growing optimism among investors, further supported by a Strong Buy consensus rating from Wall Street analysts, based on three Buy ratings over the past three months.

Forte Biosciences, listed on the Nasdaq under the ticker FBRX, operates within the Health Care sector, focusing on the development of innovative treatments for cancer and autoimmune diseases. The company’s recent achievements in the celiac disease trial underscore its commitment to addressing unmet medical needs and advancing therapeutic options for patients.

In light of these developments, Forte Biosciences is hosting a conference call to discuss the trial results in detail. The call, featuring Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the study, is scheduled for 8:30 am ET. Interested parties can join the call via the provided link or access the event and accompanying slides through the company’s investor relations section.

As Forte Biosciences moves forward with the Phase 2 trial of FB102, the biotech community and investors alike are keenly watching. The company’s progress in developing a treatment for celiac disease not only highlights its potential to make a significant impact on patient care but also represents a pivotal moment in its journey towards realizing its full potential in the biopharmaceutical industry.